Inhibition of L-Phenylalanine absorption by L-DOPA in patients with parkinsonism. 1971

A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010649 Phenylalanine An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE. Endorphenyl,L-Phenylalanine,Phenylalanine, L-Isomer,L-Isomer Phenylalanine,Phenylalanine, L Isomer
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
May 1970, Nederlands tijdschrift voor geneeskunde,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
February 1975, La Clinica terapeutica,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
February 1973, Age and ageing,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
July 1976, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
April 1969, British medical journal,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
December 1969, Journal of the Indian Medical Association,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
June 1970, Connecticut medicine,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
January 1971, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
July 1971, L' Infirmiere canadienne,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
January 1970, Acta neurologica latinoamericana,
Copied contents to your clipboard!